Brought to you by 
Crucell plans to acquire Swiss vaccines company Berna Biotech
05 Jan 2006
Executive Summary
Dutch biotech Crucell NV (antibodies/vaccines for infectious diseases) has bid to acquire public Swiss vaccines and antibody company Berna Biotech AG. The combined company, retaining the Crucell name, would be headquartered in the Netherlands and will list on the Euronext, Nasdaq, and SWX exchanges.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Crucell plans to acquire Swiss vaccines company Berna Biotech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice